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OBJECTIVES The aim of this study was to investigate the role of peripheral presynaptic alpha-2 adrenergic
receptors in modulating norepinephrine (NE) release in congestive heart failure (CHF).
BACKGROUND Activation of the sympathetic nervous system is a hallmark of CHF. Clonidine, an
imidazoline and adrenergic agonist with high selectivity for the alpha-2 adrenoceptor, has
been shown to reduce generalized sympathetic activity in heart failure after parenteral
administration. If it could be shown that peripheral presynaptic alpha-2 adrenoceptors are
inhibitory to NE release, then they could be targeted for future therapy, and as a corollary,
potentially circumvent unwanted side effects arising from stimulation of alpha-2 adrenocep-
tors in the brain. Additionally, it could be concluded that these receptors form the basis for
an auto-inhibitory feedback to further NE release.
METHODS Fifteen healthy volunteers and 10 patients with heart failure received intra-arterial clonidine
via the brachial artery (0.05 mg and 0.48 mg/100 ml forearm/min). Radio-tracer techniques
were employed for studying NE kinetics.
RESULTS Intra-arterial clonidine caused a dose-dependent decrease in forearm spillover of NE in
healthy individuals (low dose, high dose: 26%, 49%: p , 0.05, p , 0.001, respectively). In the
patient group, no decrease in forearm spillover was demonstrated after local administration.
The difference in response between the two groups was statistically significant (p 5 0.004).
CONCLUSIONS Peripheral sympathoneural alpha-2 adrenoceptors are functionally important in inhibiting
NE release in the healthy human. In heart failure, this function is lost. This finding offers
further insights into the mechanisms responsible for high circulating levels of NE in patients
with heart failure. In addition, it suggests that selective targeting of peripheral presynaptic
alpha-2 adrenoceptors will not achieve sympathoinhibition in heart failure. (J Am Coll
Cardiol 2001;37:1246–51) © 2001 by the American College of Cardiology
Congestive heart failure (CHF) is an increasingly prevalent
condition that bears a high morbidity and mortality rate. An
essential process in its pathophysiology is the activation of a
variety of neural and hormonal systems. These include the
sympathetic nervous system, the renin-angiotensin-
aldosterone axis and the endothelin system. Initially, these
responses are adaptive and act to enhance inotropy and
maintain systemic pressure by increasing peripheral vascular
resistance. Eventually, however, they lead to a worsening of
cardiovascular function and cardiac decompensation (1).
Sympathetic overactivity is characterized by elevated nor-
epinephrine (NE) spillover to plasma, especially from the
renal and cardiac beds (2), as measured by the isotope-
dilution technique (3). Sympathetic nervous activation has
been demonstrated to be associated with survival in CHF
(4,5), and elevated cardiac sympathetic activity has also been
associated with sudden death (6).
The recognition of the importance of neurohormonal
activation in CHF has resulted in a major change in our
approach to its management, from the use of symptomatic
treatment with diuretics and digitalis alone, to the utiliza-
tion of specific means to counteract the neurohormonal
derangement (1). Thus, angiotensin-converting enzyme in-
hibitors and, more recently, beta-blockers, have become
crucial in the current management of CHF (7). The use of
beta-blockers has been shown to enhance systolic function
and to improve prognosis (7). Beta-adrenergic receptor
blockade, however, does not entirely negate the detrimental
effects of the exaggerated sympathetic outflow observed in
heart failure. It cannot attenuate the effects of vasoactive
sympathetic co-transmitters, such as dopamine and neu-
ropeptide Y (8). Further, the high renal sympathetic tone in
CHF is left unchecked (2).
The next logical step in therapy of heart failure might be
to investigate the value of reducing neurotransmitter release.
Our group has previously shown that there is increased
activity of central noradrenergic neurons in heart failure, as
reflected by the increased rates of central monoamine
spillover (9). This finding has renewed interest in the
possibility of central sympathetic inhibition. While it is
known that there are sympathoinhibitory alpha-2 adrener-
gic receptors in the brainstem (10), they also exist presyn-
aptically on peripheral sympathetic nerves (11). However,
the role of these latter receptors in regulating NE release
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remains controversial. Human studies designed to study
these presynaptic receptors, using alpha-2 adrenergic ago-
nists, such as clonidine (12), and antagonists, such as
phentolamine (13), have been difficult to interpret because
of their dependence on imprecise measures of sympathetic
function, such as the venous-arterial concentration gradient
for plasma NE. The radio-tracer method that we have
previously developed and employed, however, is of greater
precision in that it recognizes and adjusts for the fact that all
organs release NE into and remove NE from the circulation
simultaneously (3).
Clonidine is a potent sympatholytic drug that has been
shown to have beneficial hemodynamic effects after acute
intravenous (IV) administration in heart failure (14). The
sympathetic inhibition achieved by clonidine has been
largely attributed to activation of alpha-2 adrenoceptors in
the central nervous system (CNS) (15). Our objective was to
clarify whether peripheral alpha-2 adrenoceptors contrib-
uted to this sympathoinhibitory action.
METHODS
Patient characteristics. The study group comprised a con-
secutive series of 10 patients with heart failure (age 58.1 6
5.8 years) and 15 healthy volunteers (45.9 6 8.5 years)
(age 6 SD). All the study subjects were male, except for one
patient with heart failure. The patients with heart failure
were all in New York Heart Association functional class II
or III. Their left ventricular ejection fraction (LVEF) was
23.8 6 4.4% (mean 6 SD). Of these patients, six had an
ischemic and four had a nonischemic cardiomyopathy. No
patient had diabetes or a diagnosed peripheral neuropathy.
All patients continued taking their normal medications. No
patient was taking a beta-blocker, alpha-2 adrenergic ago-
nist or antidepressant medication. Medications consisted of
an angiotensin-converting enzyme inhibitor, digoxin and
diuretics. Both the patients’ clinical condition and their
medications had been stable for at least one month. The
healthy control subjects were recruited by advertisement in
the general community. The study was performed with the
approval of the Alfred Hospital Ethics Review Committee
and all the subjects gave written informed consent.
Experimental procedures. All experiments were per-
formed in the morning after a light breakfast. All subjects
had refrained from smoking and consuming caffeinated
beverages over the 12 h before the procedure. Forearm
volume was measured by water displacement. Under a local
anesthetic, the brachial artery of the nondominant arm was
cannulated (3F, 5cm, Cook, Brisbane, Australia) for arterial
pressure monitoring, blood sampling and drug administra-
tion. In the same arm, the antecubital vein was cannulated
for deep venous (skeletal muscle drainage) blood sampling
(5F Hoffman sheath, Cook). This cannula was advanced
retrogradely into the forearm so that its tip could no longer
be palpable, or for a distance of 10 cm. Forearm blood flow
(FBF) was measured by strain-gauge venous occlusion
plethysmography (16). For each determination, four to five
measurements were performed, and the results were aver-
aged. Hand blood flow was excluded by the use of a cuff at
the wrist that was inflated to suprasystolic levels.
Study protocol. The NE isotope-dilution technique, as
previously developed by this laboratory (3,17), was em-
ployed to provide a biochemical index of global and forearm
sympathetic nerve activity. In brief, tritiated levo-(7-3H)-
norepinephrine (New England Nuclear, Boston, Massachu-
setts) was infused at a rate of 0.5 to 1 mCi/min through a
peripheral vein for 45 min to achieve steady-state plasma
concentrations. Once steady-state had been achieved, base-
line FBF was measured. Arterial and deep venous samples
were obtained for calculation of forearm and global NE
spillover. Then, clonidine (Boehringer-Ingleheim, In-
gelheim, Germany) was infused into the brachial artery at
0.05 mg/100 ml forearm/5 min. The FBF measurements
and blood sampling were again undertaken. Immediately
after this, clonidine was administered intra-arterially (I/A)
at 0.48 mg/100 ml forearm/5 min (12). All measurements
were then repeated.
After an interval of .30 min, IV clonidine was succes-
sively administered at two doses, 1 and 2 mg/kg, each
infused over 10 min. At the end of each infusion, FBF and
blood sampling for catecholamine spillover was again per-
formed.
Analysis of plasma catecholamines. Blood samples were
collected into ice-chilled tubes containing an anticoagulant,
ethyleneglycol-bis (beta-amino-ethyl ether) N,N9tetraacetic
acid (EGTA) and reduced glutathione to prevent oxidation.
After centrifugation at 4°C, plasma samples were stored at
270°C until assayed. Norepinephrine plasma concentra-
tions were determined by high performance liquid chroma-
tography with electrochemical detection as previously de-
scribed (18). The plasma tritiated NE concentration was
determined by liquid scintillation spectroscopy after collec-
tion of the eluant from the electrochemical detector cell
using a fraction collector.
Norepinephrine spillover measurements. Total body NE
spillover rate was calculated as follows:
Abbreviations and Acronyms
ANOVA 5 analysis of variance
CHF 5 congestive heart failure
CNS 5 central nervous system
FBF 5 forearm blood flow
FSO 5 forearm spillover
I/A 5 intra-arterial
IV 5 intravenous
LVEF 5 left ventricular ejection fraction
NE 5 norepinephrine
NS 5 not significant
PAR 5 plasma appearance rate
PF 5 plasma flow
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Total NE spillover 5
@3H#NE infusion rate
Plasma NE specific activity
Forearm spillover ~FSO! of NE 5 @~CV 2 CA!
1 CA 3 ~NEE!] 3 ~PF!
Where, CV is the plasma NE concentration in the deep
forearm vein, CA is the arterial plasma NE concentration,
and NEE is the fractional extraction of radiolabeled NE
across the forearm.
Recognizing that regional spillover can be influenced by
blood flow, we also calculated the plasma appearance rate
(PAR) of NE, as described by Chang et al. (16):
PAR 5
FSO of NE
1 2 @NEE#
Statistical analysis. Data are presented as mean value 6
SEM, unless otherwise stated. Statistical analysis was per-
formed using statistical software (SigmaStat, version 2.03,
Chicago, Illinois). Within-group analysis was performed
using one-way repeated measures analysis of variance
(ANOVA) and the Tukey Test was employed in post-hoc
analysis. Group differences were obtained using two-way
repeated measures ANOVA with the Bonferroni multiple
comparison test. A p value of ,0.05 was considered
statistically significant.
RESULTS
The baseline comparisons between the two groups are given
in Table 1. There was no significant difference in baseline
FBF and FSO of NE. However, the patient group had a
much higher total body spillover of NE than the healthy
control subjects.
Effects of I/A clonidine. As expected, I/A clonidine at the
two doses did not result in any significant changes in global
NE spillover (control 1.86 6 0.33 to 1.87 6 0.27, 1.86 6
0.28 nmol/min and CHF 5.26 6 1.39 to 4.44 6 1.1, 4.33 6
1.2 nmol/min).
Intra-arterial clonidine caused a decrease in FBF in both
groups (Fig. 1A and 1B). At the low dose, there was a small,
nonsignificant fall in FBF: 21.3 6 3.8 to 19.4 6 2.7 ml/min
in the control group and 24.7 6 7.35 to 23.2 6 6.4 ml/min
in the patient group. With the high dose, the changes in
FBF were: 21.3 6 3.8 to 15.4 6 2.0 ml/min (p 5 0.01) and
24.7 6 7.35 to 14.8 6 3.5 ml/min (p 5 0.015), respectively.
At the higher dose, this represented a decrease in FBF in
the control and patient groups of 28% and 40%, respectively
(p 5 NS for between groups comparison).
With low dose I/A clonidine, FSO of NE in the control
group decreased from 12.1 6 1.4 to 8.96 6 1.18 pmol/min
(p 5 0.03). In the patient group, a nonsignificant increase in
FSO was seen from baseline of 8.97 6 2.65 to 14.3 6
6.23 pmol/min. High dose I/A clonidine resulted in a
change from 12.1 6 1.4 to 6.19 6 1.01 pmol/min (p ,
0.001) and 8.97 6 2.65 to 11.88 6 5.72 pmol/min (p 5
NS), respectively (Fig. 2A and 2B). The difference in the
response to I/A clonidine between the two groups (decrease
by 49% and increase by 32%) was significant (p 5 0.004).
Since regional NE spillover is to some extent dependent
on blood flow (19), we also calculated the PAR of NE in the
forearm, as described by Chang et al. (16). In the control
group, PAR (in pmol/min) decreased from 30.3 6 7.4 to
18.1 6 3.4 (p , 0.05) and to 14.7 6 3.6 (p , 0.001) with
the two doses of I/A clonidine. In the patient group, the
change in PAR (in pmol/min) was from 9.1 6 2.4 to 13.9 6
7.2 (p 5 NS) and to 13.5 6 3.3 (p 5 NS). Again, as with
FSO, the difference in response to I/A clonidine between
the groups was significant (p 5 0.005).
Effects of IV clonidine. Intravenous clonidine resulted in a
reduction in the systolic blood pressure: in the control group,
from 134 6 5.8 to 127 6 4.4 and 114.3 6 4.0 mm Hg, p 5
0.02 and p , 0.001, respectively and in the patient group, from
125.8 6 9.8 to 116.4 6 9.2 and 100.2 6 6.2 mm Hg, p 5 NS
and p 5 0.01, respectively. There was no significant change in
FBF in either group with intravenous administration.
Table 1. Baseline Characteristics
Parameter Control Heart Failure p Value
FBF, ml/min 21.3 6 3.8 24.7 6 7.3 NS
FSO, pmol/min 12.1 6 1.4 8.97 6 2.65 NS
TBS, nmol/min 1.86 6 0.33 5.26 6 1.39 0.01
FBF 5 forearm blood flow; FSO 5 forearm spillover of norepinephrine; NS 5
nonsignificant; TBS 5 total body spillover of norepinephrine.
Figure 1. (A) Line graph represents the change in forearm blood flow
(FBF) in response to intra-arterial (IA) clonidine, in healthy volunteers
(n 5 15). (B) Line graph represents the change in FBF in response to I/A
clonidine, in patients with congestive heart failure (n 5 10).
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In the control subjects, IV clonidine resulted in a decrease in
FSO (12.1 6 1.4 to 6.87 6 0.95 and 3.12 6 0.70 pmol/min,
p , 0.001). In patients with CHF, IV clonidine elicited a
change in FSO from 8.97 6 2.65 to 10.2 6 4.1 at low dose
and 5.43 6 3.25 pmol/min at the higher dose (p 5 0.06).
When examining the effects of IV clonidine on global
NE spillover, the following results were obtained: in the
healthy subjects, 1.86 6 0.33 to 1.62 6 0.28 and 1.01 6
0.18 nmol/min, p 5 NS and p , 0.001; in the patients,
5.26 6 1.39 to 3.49 6 0.84 and 2.48 6 0.74 nmol/min, p 5
NS and p 5 0.004.
DISCUSSION
Clonidine has been shown to decrease cardiac and global
NE spillover in heart failure when administered parenterally
(14,20). It is highly lipophilic and its major site of action has
been presumed to be at the central alpha-2 adrenoceptors on
sympathoinhibitory neurons in the brain stem (15). A
deterrent to its long-term use is sedation and depression, as
a result of activation of these receptors. In the periphery,
there are known to be alpha-2 adrenergic receptors located
presynaptically and postsynaptically at sympathetic nerve
terminals (11). The role of these receptors in modulating
peripheral neurotransmitter release in heart failure has not
been elucidated. If these receptors are physiologically active,
then future drug therapy could be targeted at them. In so
doing, direct sympathetic attenuation could be achieved
without the side effects resulting from central alpha-2
adrenoceptor activation.
There is some evidence that, in health, neuronal alpha-2
adrenoceptors are functionally important in reducing NE
release (21). However, it is not known whether in heart
failure, in the presence of chronic overexposure to neuro-
transmitter, changes in receptor number or function or both
take place. The strongest evidence for such a phenomenon
is in the down-regulation of beta-1 adrenoceptors that
occurs in the failing heart (22). Previous investigators have
demonstrated that the number of platelet alpha-2 adreno-
ceptors is decreased in heart failure, having established that
human platelets have an alpha-2 adrenoceptor density
similar to those present on the nerve terminals (23). In the
absence of sympathetic innervation of platelets, the rele-
vance of this finding is uncertain. In another study, there
was a decreased sensitivity to IV clonidine in patients with
CHF (24), when compared with control subjects. However,
systemic administration cannot selectively study the role of
the peripheral alpha-2 adrenoceptors.
Effects of I/A clonidine on regional blood flow and NE
release. The novel finding of this study is that NE spillover
in the healthy forearm is substantially reduced by clonidine
given I/A, but that this effect is lost in the patients with
heart failure. This indicates a down-regulation of the
peripheral alpha-2 adrenoceptor in heart failure.
As others have previously found, I/A clonidine does result
in a reduction in FBF (12), and in our study, this effect was
preserved in CHF. Most of the postsynaptic alpha-
adrenergic receptors located within the nerve junction are
the alpha-1 type (11). Clonidine has a high, though not
absolute, selectivity for the alpha-2 type adrenoceptor (12),
so that the demonstrated reduction in FBF in patients with
CHF may be due to vasoconstriction caused by activation of
the postsynaptic alpha-1 adrenoceptors on vascular smooth
muscle. Alternatively, in heart failure, down-regulation of
neuronal presynaptic alpha-2 adrenoceptors may occur in
the absence of down-regulation of the vascular alpha-2
adrenoceptors, which remain capable of eliciting unim-
paired vasoconstriction.
It is appreciated that regional spillover of NE is altered
by changes in blood flow, decreasing with declining flow,
probably due to increased NE extraction locally (19).
However, the reduction in forearm NE spillover in the
control group observed in this study is likely to have resulted
from true inhibition of NE release, rather than from a
reduction in flow. Firstly, on existing evidence, a reduction
in regional NE release of 50% with I/A clonidine is too
profound to have resulted alone from a flow reduction of
28% (3,17). Secondly, the plasma NE appearance rate,
which has been proposed to be a largely flow independent
measure (16), also showed a similar dose-dependent reduc-
tion in forearm NE spillover with clonidine. Finally, and
Figure 2. (A) Line graph represents the forearm spillover (FSO) of
norepinephrine (NE) in response to intra-arterial (I/A) clonidine, in
healthy volunteers (n 5 15). (B) Line graph represents the FSO of NE in
response to I/A clonidine, in patients with congestive heart failure (n 5 10)
(p 5 NS).
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perhaps most importantly, no reduction in regional NE
release was seen with local alpha-2 adrenoceptor stimulation
in the heart failure group, despite a 40% decrease in FBF, a
reduction that was similar in magnitude to that observed in
the control group.
Effects of systemic clonidine on regional NE spillover.
The well-recognized sympathoinhibitory actions of IV
clonidine have been explained pharmacologically in the
context of two possible sites of action: in the periphery on
sympathetic nerves, and the brain centers controlling sym-
pathetic outflow. In the present study, control subjects
demonstrated a dramatic reduction in regional (74%)
and global NE (46%) spillover. In the patients with heart
failure, IV clonidine resulted in a 54% reduction in global
NE release with the high dose; however, only a trend to
reduction in regional NE spillover was seen. An explanation
for these disparate effects of IV clonidine on forearm
spillover of NE in CHF could be that the major determi-
nant of forearm NE spillover is local, rather than central
alpha-2 adrenoceptor activity, and that these auto-
inhibitory peripheral receptors in heart failure are down-
regulated, with preservation of the central alpha-2 adreno-
ceptors. Alternatively, it is also possible that, in heart
failure, there is a global down-regulation of the alpha-2
adrenoceptor (24), and the inhibitory effects on whole body
NE spillover are mediated through central imidazoline
receptors (25).
Clinical implications. Moxonidine, an imidazoline ligand
acting on the CNS receptors to decrease sympathetic
activation, has been demonstrated to result in a dramatic
reduction in global NE release in patients with heart failure
(26). It should be noted that the MOXCON study, de-
signed to examine the effect of moxonidine in heart failure,
was recently terminated because of excess mortality in the
treatment group. Moxonidine has a powerful sympatholytic
action (26), and it is unclear why this favorable effect should
be associated with excess mortality in heart failure. A
detailed report of the study is yet to be published.
CONCLUSIONS
The present study aimed to clarify the importance of
presynaptic alpha-2 adrenoceptors in the regulation of NE
release in health and in heart failure. When compared with
control subjects, we found evidence of a substantial down-
regulation of peripheral alpha-2 adrenoceptors functionality
in CHF. These data, therefore, mitigate against a likely
clinical role for agents that specifically target these receptors.
As a further conclusion, the findings suggest that the lack of
sympathoinhibitory activity demonstrated by these receptors
in heart failure may possibly contribute to the higher NE
release in CHF, due to a failure of the auto-inhibitory
feedback mechanism in the synaptic cleft (27).
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